Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BYJournal of clinical medicine

Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

  • Osama Odeh1
  • Mariam Al-Bayati2
  • Ali Abdulrazzaq3
  • Ala W. Abdallah4
  • Kanval Shah5
5 affiliations
  1. 1Department of Internal Medicine, Houston Methodist The Woodlands Hospital, Conroe, TX 77385, USA
  2. 2Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
  3. 3Department of Internal Medicine, Brookdale Hospital Medical Center, Brooklyn, NY 11212, USA
  4. 4Division of Cardiology, LSU Health Sciences Center, Louisiana State University Health Sciences Center, Shreveport, LA 70802, USA
  5. 5Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist The Woodlands Hospital, Conroe, TX 77385, USA
Read full textPDFDOICite

Abstract

Background: Acute myocardial infarction-related cardiogenic shock (AMI-CS) remains associated with high mortality despite advances in revascularization, critical care, and temporary mechanical circulatory support (MCS). Recent randomized trials have challenged the concept of routine device-based therapy and highlighted the importance of matching MCS strategy to shock phenotype, timing, and patient risk profile. Methods: We reviewed contemporary randomized clinical trials and prespecified or post hoc analyses evaluating temporary MCS strategies in adult patients with AMI-CS. PubMed was searched for English-language studies published from January 2021 through June 2026, focusing on intra-aortic balloon pump (IABP), microaxial flow pumps, and venoarterial extracorporeal membrane oxygenation (VA-ECMO/ECLS). Outcomes of interest included mortality, hemodynamic recovery, end-organ outcomes, and device-related complications. Results: Recent randomized evidence demonstrates that no temporary MCS device provides universal benefit across the heterogeneous AMI-CS population. Routine IABP use has not been associated with improved survival and is now reserved for selected patients requiring modest circulatory support, bridge-to-decision strategies, or specific mechanical complications. The DanGer Shock trial provided the strongest contemporary randomized evidence supporting temporary MCS, demonstrating reduced 180-day mortality with routine Impella CP support in carefully selected patients with STEMI-related cardiogenic shock. However, this benefit was accompanied by increased major bleeding, limb ischemia, acute kidney injury, and renal replacement therapy. Prespecified secondary and exploratory post hoc analyses have generated hypotheses that treatment response may vary according to age, baseline hemodynamics, timing of support, and shock phenotype; however, these findings require prospective validation and should not be interpreted as established treatment-selection criteria. In contrast, ECLS-SHOCK, ECMO-CS, EURO SHOCK, and randomized meta-analytic data did not demonstrate a survival benefit for routine early VA-ECMO in broad AMI-CS populations and consistently identified higher rates of bleeding and vascular complications. Strategies for routine early left ventricular unloading during VA-ECMO have improved physiologic parameters but have not demonstrated a mortality benefit. Conclusions: Contemporary randomized trials have shifted the role of temporary MCS in AMI-CS from routine device deployment toward individualized, phenotype-guided therapy. Impella CP, as evaluated in the DanGer Shock trial, currently provides the strongest randomized survival signal but should be applied selectively in patients with predominantly left ventricular failure treated within experienced shock systems. VA-ECMO remains an important rescue option in carefully selected patients with refractory circulatory collapse, severe hypoxemia, cardiac arrest, or biventricular failure, although routine early use is not supported. Future research should focus on earlier shock phenotyping, physiology-guided device selection, complication reduction, and strategies that integrate mechanical support with recovery-focused care.

Related

  1. Comparative efficacy and safety of mechanical circulatory support in ST-elevation myocardial infarction with cardiogenic shock: a network meta-analysis
    Boyu Guan, Xinsheng Li, Jiahua Zhang +4
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossref
  2. Defining cost-effectiveness of mechanical circulatory support escalation among patients with acute myocardial infarction complicated by cardiogenic shock
    A. Kamalakkannan, Y. Yang, R. Batchelor +12
    medRxivPreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
  3. Mechanical circulatory support strategy in post-myocardial infarction ventricular septal defect repair.
    Caroline A Magro, Caroline Snyder, Katherine Phillips +4
    JTCVS openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  4. Mortality risk stratification in contemporary myocardial infarction-related cardiogenic shock: development of AMICS-ADMIT prediction model and benchmarking of established scores.
    Klevis Mihali, Birgit Markus, Kornelia Neuner +7
    International journal of cardiology. Heart & vasculaturePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  5. Mechanical Complications After Acute Myocardial Infarction: Contemporary Management, Treatment Selection, and Outcomes in a 10-Year Regional Referral Network
    Alberto Alén, Andrés Álvarez-Gato, Manuel Sánchez +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{odeh2026temporary,
  title = {{Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials}},
  author = {Osama Odeh and Mariam Al-Bayati and Ali Abdulrazzaq and Ala W. Abdallah and Kanval Shah},
  journal = {Journal of clinical medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15197664},
  url = {https://europepmc.org/article/PMC/PMC13665844},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials
AU  - Osama Odeh
AU  - Mariam Al-Bayati
AU  - Ali Abdulrazzaq
AU  - Ala W. Abdallah
AU  - Kanval Shah
PY  - 2026
DA  - 2026/10/01
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15197664
UR  - https://europepmc.org/article/PMC/PMC13665844
AB  - Background: Acute myocardial infarction-related cardiogenic shock (AMI-CS) remains associated with high mortality despite advances in revascularization, critical care, and temporary mechanical circulatory support (MCS). Recent randomized trials have challenged the concept of routine device-based therapy and highlighted the importance of matching MCS strategy to shock phenotype, timing, and patient risk profile. Methods: We reviewed contemporary randomized clinical trials and prespecified or post hoc analyses evaluating temporary MCS strategies in adult patients with AMI-CS. PubMed was searched for English-language studies published from January 2021 through June 2026, focusing on intra-aortic balloon pump (IABP), microaxial flow pumps, and venoarterial extracorporeal membrane oxygenation (VA-ECMO/ECLS). Outcomes of interest included mortality, hemodynamic recovery, end-organ outcomes, and device-related complications. Results: Recent randomized evidence demonstrates that no temporary MCS device provides universal benefit across the heterogeneous AMI-CS population. Routine IABP use has not been associated with improved survival and is now reserved for selected patients requiring modest circulatory support, bridge-to-decision strategies, or specific mechanical complications. The DanGer Shock trial provided the strongest contemporary randomized evidence supporting temporary MCS, demonstrating reduced 180-day mortality with routine Impella CP support in carefully selected patients with STEMI-related cardiogenic shock. However, this benefit was accompanied by increased major bleeding, limb ischemia, acute kidney injury, and renal replacement therapy. Prespecified secondary and exploratory post hoc analyses have generated hypotheses that treatment response may vary according to age, baseline hemodynamics, timing of support, and shock phenotype; however, these findings require prospective validation and should not be interpreted as established treatment-selection criteria. In contrast, ECLS-SHOCK, ECMO-CS, EURO SHOCK, and randomized meta-analytic data did not demonstrate a survival benefit for routine early VA-ECMO in broad AMI-CS populations and consistently identified higher rates of bleeding and vascular complications. Strategies for routine early left ventricular unloading during VA-ECMO have improved physiologic parameters but have not demonstrated a mortality benefit. Conclusions: Contemporary randomized trials have shifted the role of temporary MCS in AMI-CS from routine device deployment toward individualized, phenotype-guided therapy. Impella CP, as evaluated in the DanGer Shock trial, currently provides the strongest randomized survival signal but should be applied selectively in patients with predominantly left ventricular failure treated within experienced shock systems. VA-ECMO remains an important rescue option in carefully selected patients with refractory circulatory collapse, severe hypoxemia, cardiac arrest, or biventricular failure, although routine early use is not supported. Future research should focus on earlier shock phenotyping, physiology-guided device selection, complication reduction, and strategies that integrate mechanical support with recovery-focused care.
SN  - 2077-0383
ER  -